Chemistry:Asunaprevir
From HandWiki
Short description: Compound
| |
| Names | |
|---|---|
| IUPAC name
3-Methyl-N-{[(2-methyl-2-propanyl)oxy]carbonyl}-L-valyl-(4R)-4-[(7-chloro-4-methoxy-1-isoquinolinyl)oxy]-N-{(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-vinylcyclopropyl}-L-prolinamide
| |
| Systematic IUPAC name
tert-Butyl {(2S)-1-[(32S,34R,61R,62S)-17-chloro-62-ethenyl-14-methoxy-4,7,9,9-tetraoxo-2-oxa-9λ6-thia-5,8-diaza-1(1)-isoquinolina-3(4,2)-pyrrolidina-6(1,1),10(1)-dicyclopropadecaphan-31-yl]-3,3-dimethyl-1-oxobutan-2-yl}carbamate | |
| Other names
BMS-650032
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| KEGG | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C35H46ClN5O9S | |
| Molar mass | 748.29 g·mol−1 |
| Pharmacology | |
| 1=ATC code }} | J05AP06 (WHO) |
| Legal status | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Asunaprevir (formerly BMS-650032, brand name in Japan and Russia [2] Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013.[3]
Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3.[4] Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.[5][6][7]
References
- ↑ "Prescription medicines: registration of new chemical entities in Australia, 2015". 21 June 2022. https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia-2015.
- ↑ "Sunvepra (asunaprevir) soft gelatin capsules 100 mg. Registration certificate" (in Russian). http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=374742&t=. Retrieved 26 August 2015.
- ↑ "A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients". ClinicalTrials.gov. 23 September 2015. http://clinicaltrials.gov/ct2/show/NCT01497834.
- ↑ C. Reviriego (2012). "Asunaprevir. HCV serine protein NS3 inhibitor, Treatment of hepatitis C virus". Drugs of the Future 37 (4): 247–254. doi:10.1358/dof.2012.037.04.1789350. https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1789350&p_IsPs=N.
- ↑ "Preliminary study of two antiviral agents for hepatitis C genotype 1". The New England Journal of Medicine 366 (3): 216–24. January 2012. doi:10.1056/NEJMoa1104430. PMID 22256805.
- ↑ "Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study". Bloomberg. Apr 19, 2012. https://www.bloomberg.com/news/2012-04-19/bristol-myers-daclatasvir-asunaprevir-cured-77-study.html.
- ↑ AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders . Highleyman, L. HIVandHepatitis.com. 8 November 2011.
 |  |
